The efficacy of moxifloxacin-based triple-therapy 
in first-line treatment of Helicobacter pylori infection 
in Pakistan: randomized controlled trials

Sumaira Khadim; Iyad Naeem; Muhammad Alam; Hina Rehman; Sidra Ghayas; Sajjad Haider

doi:10.5114/amscd.2023.131926

ISSN: 2451-0637

Archives of Medical Science - Civilization Diseases

Current volume

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

1/2023
vol. 8

Send email

Copy url:

abstract:

Clinical research

The efficacy of moxifloxacin-based triple-therapy in first-line treatment of Helicobacter pylori infection in Pakistan: randomized controlled trials

Sumaira Khadim

¹

,

Iyad Muhammad Naeem

¹

,

Muhammad Tanveer Alam

²

,

Hina Rehman

³

,

Sidra Ghayas

¹

,

Sajjad Haider

¹

Department of Pharmaceutics and Pharmacy Practice, University of Karachi, Karachi, Pakistan
Department of Gastroenterology, Jamal Noor Hospital, Jamal, Pakistan
Department of Pharmacy Practice, Jinnah Sindh Medical University, Karachi, Pakistan

Arch Med Sci Civil Dis 2023; 8: e31–e37

DOI: https://doi.org/10.5114/amscd.2023.131926

Online publish date: 2023/09/30

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Khadim S, Naeem IM, Alam MT, Rehman H, Ghayas S, Haider S. The efficacy of moxifloxacin-based triple-therapy 
in first-line treatment of Helicobacter pylori infection 
in Pakistan: randomized controlled trials. Archives of Medical Science - Civilization Diseases. 2023;8(1):31-37. doi:10.5114/amscd.2023.131926.

APA

Khadim, S., Naeem, I. M., Alam, M. T., Rehman, H., Ghayas, S.,  & Haider, S. (2023). The efficacy of moxifloxacin-based triple-therapy 
in first-line treatment of Helicobacter pylori infection 
in Pakistan: randomized controlled trials. Archives of Medical Science - Civilization Diseases, 8(1), 31-37. https://doi.org/10.5114/amscd.2023.131926

Chicago

Khadim, Sumaira, Iyad M Naeem, Muhammad T Alam, Hina Rehman, Sidra Ghayas,  and Sajjad Haider. 2023. "The efficacy of moxifloxacin-based triple-therapy 
in first-line treatment of Helicobacter pylori infection 
in Pakistan: randomized controlled trials". Archives of Medical Science - Civilization Diseases 8 (1): 31-37. doi:10.5114/amscd.2023.131926.

Harvard

Khadim, S., Naeem, I., Alam, M., Rehman, H., Ghayas, S.,  and Haider, S. (2023). The efficacy of moxifloxacin-based triple-therapy 
in first-line treatment of Helicobacter pylori infection 
in Pakistan: randomized controlled trials. Archives of Medical Science - Civilization Diseases, 8(1), pp.31-37. https://doi.org/10.5114/amscd.2023.131926

MLA

Khadim, Sumaira et al. "The efficacy of moxifloxacin-based triple-therapy 
in first-line treatment of Helicobacter pylori infection 
in Pakistan: randomized controlled trials." Archives of Medical Science - Civilization Diseases, vol. 8, no. 1, 2023, pp. 31-37. doi:10.5114/amscd.2023.131926.

Vancouver

Khadim S, Naeem I, Alam M, Rehman H, Ghayas S, Haider S. The efficacy of moxifloxacin-based triple-therapy 
in first-line treatment of Helicobacter pylori infection 
in Pakistan: randomized controlled trials. Archives of Medical Science - Civilization Diseases. 2023;8(1):31-37. doi:10.5114/amscd.2023.131926.

PlumX metrics:

Introduction
The challenge of eradicating Helicobacter pylori through antibiotic treatment is still a significant concern due to the existence of antibiotic resistance. This study aimed to evaluate and compare the efficacy of sequential therapy based on levofloxacin versus triple therapy based on moxifloxacin in treating H. pylori infection in patients receiving first-line treatment.

Material and methods
A total of 162 patients who were examined positive for H. pylori were randomly assigned to either of 2 groups to receive the following: (a) levofloxacin 500mg BID, amoxicillin 1 g BID, and omeprazole 20 mg BID for the first 5 days, followed by levofloxacin 500 mg BID, tinidazole 500 mg BID, and omeprazole 20 mg BID (LAO-LTO group); or (b) moxifloxacin 400 mg OD, amoxicillin 1 g BID, and omeprazole 20 mg BID (MAO group) for 10 days.

Results
The eradication rate of H. pylori in the LAO-LTO group was 58.4% (45/77) and 76.3% (45/59), and in the MAO group it was 81.2% (69/85) and 92% (69/75), respectively, in ITT and PP analyses. Eradication rates of moxifloxacin-based triple therapies were significantly higher than those of levofloxacin-based regimens (p < 0.001). The overall incidence of side effects and patient compliance was significantly lower in the moxifloxacin group (p < 0.005) than in the levofloxacin group.

Conclusions
Moxifloxacin-based triple therapy could be a significantly more effective first-line eradication treatment as compared to levofloxacin-based sequential therapy for H. pylori infection in Pakistan.

keywords:

The efficacy of moxifloxacin-based triple-therapy in first-line treatment of Helicobacter pylori infection in Pakistan: randomized controlled trials

Sumaira Khadim 1 , Iyad Muhammad Naeem 1 , Muhammad Tanveer Alam 2 , Hina Rehman 3 , Sidra Ghayas 1 , Sajjad Haider 1

comparison, eradication, Helicobacter pylori, levofloxacin

Sumaira Khadim

¹

,

Iyad Muhammad Naeem

¹

,

Muhammad Tanveer Alam

²

,

Hina Rehman

³

,

Sidra Ghayas

¹

,

Sajjad Haider

¹